

Zomig vs. Maxalt: Patient Satisfaction Study  
Accepted for presentation  
at the 16<sup>th</sup> Annual Diamond Headache Meeting:  
Headache Update 2002, July 16 – 20, 2002

A Comparison of the Maxalt, MLT and the Zomig, ZMT

## Abstract

Multiple head-to-head studies have shown comparable efficacy among all of the oral triptans<sup>1</sup>. The purpose of this study was to compare two oral dissolving triptans, Zomig and Maxalt. The main objective was to ask the participants their preference after a trial of both triptans. The efficacy was only a minor objective. The study was conducted open-labeled, with fixed dosing and in a single-center. Subjects received treatment on an outpatient basis. All subjects were given four Zomig ZMT 2.5mg tablets and four Maxalt MLT 10mg tablets. They treated four migraines, two with each medication. The significance of this study is that despite no difference in efficacy, patients had a perceived difference in speed of relief and which medication worked better. There was also a preference in taste. In the practice setting, patients are becoming more and more knowledgeable about drugs and insistent on options. We must respect this, offer each triptan and let the patient decide which medication works best for him or her. Migraines are a complex disease to treat and as this group demonstrated, the new onset migraine, triptan naïve patient is not common. Many patients have had migraines for years and have tried a triptan, but it is worth giving them the option of trying another.